Inner Mongolia Furui Med Sci (300049) - Total Assets
Based on the latest financial reports, Inner Mongolia Furui Med Sci (300049) holds total assets worth CN¥3.42 Billion CNY (≈ $500.54 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 300049 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Inner Mongolia Furui Med Sci - Total Assets Trend (2006–2025)
This chart illustrates how Inner Mongolia Furui Med Sci's total assets have evolved over time, based on quarterly financial data. Check how high is Inner Mongolia Furui Med Sci's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Inner Mongolia Furui Med Sci - Asset Composition Analysis
Current Asset Composition (December 2025)
Inner Mongolia Furui Med Sci's total assets of CN¥3.42 Billion consist of 44.9% current assets and 55.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 18.9% |
| Accounts Receivable | CN¥581.99 Million | 16.9% |
| Inventory | CN¥148.97 Million | 4.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥583.23 Million | 17.0% |
| Goodwill | CN¥179.50 Million | 5.2% |
Asset Composition Trend (2006–2025)
This chart illustrates how Inner Mongolia Furui Med Sci's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Inner Mongolia Furui Med Sci market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Inner Mongolia Furui Med Sci's current assets represent 44.9% of total assets in 2025, a decrease from 47.6% in 2006.
- Cash Position: Cash and equivalents constituted 18.9% of total assets in 2025, up from 17.1% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 21.0% of total assets, an increase from 10.0% in 2006.
- Asset Diversification: The largest asset category is intangible assets at 17.0% of total assets.
Inner Mongolia Furui Med Sci Competitors by Total Assets
Key competitors of Inner Mongolia Furui Med Sci based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Inner Mongolia Furui Med Sci - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.44 | 4.56 | 3.97 |
| Quick Ratio | 3.10 | 4.14 | 3.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.08 Billion | CN¥1.19 Billion | CN¥823.26 Million |
Inner Mongolia Furui Med Sci - Advanced Valuation Insights
This section examines the relationship between Inner Mongolia Furui Med Sci's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.42 |
| Latest Market Cap to Assets Ratio | 0.45 |
| Asset Growth Rate (YoY) | 12.4% |
| Total Assets | CN¥3.44 Billion |
| Market Capitalization | $1.55 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Inner Mongolia Furui Med Sci's assets below their book value (0.45x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Inner Mongolia Furui Med Sci's assets grew by 12.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Inner Mongolia Furui Med Sci (2006–2025)
The table below shows the annual total assets of Inner Mongolia Furui Med Sci from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.44 Billion ≈ $503.22 Million |
+12.42% |
| 2024-12-31 | CN¥3.06 Billion ≈ $447.61 Million |
+15.54% |
| 2023-12-31 | CN¥2.65 Billion ≈ $387.41 Million |
+4.93% |
| 2022-12-31 | CN¥2.52 Billion ≈ $369.21 Million |
-0.06% |
| 2021-12-31 | CN¥2.52 Billion ≈ $369.43 Million |
+10.22% |
| 2020-12-31 | CN¥2.29 Billion ≈ $335.18 Million |
+1.79% |
| 2019-12-31 | CN¥2.25 Billion ≈ $329.28 Million |
+5.33% |
| 2018-12-31 | CN¥2.14 Billion ≈ $312.62 Million |
-14.90% |
| 2017-12-31 | CN¥2.51 Billion ≈ $367.37 Million |
+4.32% |
| 2016-12-31 | CN¥2.41 Billion ≈ $352.17 Million |
+17.92% |
| 2015-12-31 | CN¥2.04 Billion ≈ $298.65 Million |
+53.32% |
| 2014-12-31 | CN¥1.33 Billion ≈ $194.80 Million |
+16.59% |
| 2013-12-31 | CN¥1.14 Billion ≈ $167.08 Million |
+23.09% |
| 2012-12-31 | CN¥927.58 Million ≈ $135.73 Million |
+6.20% |
| 2011-12-31 | CN¥873.44 Million ≈ $127.81 Million |
+9.78% |
| 2010-12-31 | CN¥795.66 Million ≈ $116.43 Million |
+217.04% |
| 2009-12-31 | CN¥250.96 Million ≈ $36.72 Million |
+12.49% |
| 2008-12-31 | CN¥223.10 Million ≈ $32.65 Million |
+11.03% |
| 2007-12-31 | CN¥200.93 Million ≈ $29.40 Million |
+6.99% |
| 2006-12-31 | CN¥187.80 Million ≈ $27.48 Million |
-- |
About Inner Mongolia Furui Med Sci
Inner Mongolia Furui Medical Science Co., Ltd. engages in the production and sale of pharmaceutical drugs in China and internationally. The company also engages in the research and development and sales of diagnostic equipment and related medical services. It offers FibroScan series of liver fibrosis diagnostic instruments; FibroMeter series of blood test analysis tools for evaluating chronic liv… Read more